PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California.\', \'Division of Abdominal Transplantation, Department of Surgery, Stanford University School of Medicine, Stanford, California.\', \'Pharmacy Manager of Clinical Effectiveness, Department of Pharmacy, Stanford Health Care, Stanford, California.\', \'Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California.\', \'Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California.\', \'Department of Pathology, Stanford University School of Medicine, Stanford, California.\', \'Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, California.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.34067/KID.0005732021
?:hasPublicationType
?:journal
  • Kidney360
is ?:pmid of
?:pmid
?:pmid
  • 35368573
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all